Abstract
BackgroundThe use of biological disease modifying anti-rheumatic drugs (bDMARDs) or synthetic DMARDs for the treatment of rheumatoid arthritis (RA) has improved the management of RA and prevented patients with RA...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
